(Q40717390)

23 September 2017

0 references

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials (English)

1 reference

23 September 2017

1 reference

Unger JM

1

1 reference

23 September 2017

Flaherty LE

2

1 reference

23 September 2017

Liu PY

3

1 reference

23 September 2017

Albain KS

4

1 reference

23 September 2017

Sondak VK

5

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

23 September 2017

1 reference

23 September 2017

91

1 reference

23 September 2017

1148-1155

1 reference

23 September 2017

6

1 reference

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

23 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Prognostic factors in metastatic malignant melanoma. The southeastern cancer study group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Malignant melanoma: sex differences in survival after evidence of distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Prognostic factors in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Application of multistage Markov modeling to malignant melanoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

High-dose cisplatin in disseminated melanoma: a comparison of two schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

A new American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Metastatic patterns of choroidal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Malignant melanoma: an androgen-dependent tumour?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Regression analyses of prognostic factors in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010315%2991%3A6%3C1148%3A%3AAID-CNCR1111%3E3.0.CO%3B2-%23

10.1002/1097-0142(20010315)91:6<1148::AID-CNCR1111>3.0.CO;2-#

21 January 2018

Identifiers

DOI

1 reference

release_jfs4uaap55dg7byvzsaihgqh5e

23 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jfs4uaap55dg7byvzsaihgqh5e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference